I t's exactly 1 week from Christmas as I begin to write this page for issue 6.1 of IJLEW. In many ways it is a good time to reflect on where we have come from and where the future may be headed. For me these thoughts are focused on principally 2 issues: research in wound healing and improving clinical management in wound healing.
Over 2 decades ago, it appeared that the emergence of reliable techniques useful in the study of the microcirculation would push back the boundaries of knowledge in wound science. We learned that tissues surrounding some chronic wounds could exist in a state of relative hypoxia that neither supported healing nor permitted further breakdown. We never seem to have figured out how to perturbate this tricky equilibrium. We also learned that tissue synthesis in chronic wounds is unlikely to be the problem; rather, excessive breakdown caused by elevated levels of some matrix metalloproteinases was evident and that we should consider dealing with this aspect of wound biology. But by far the most exciting announcement was that certain growth factors might hold the key to wound healing.
Through the late nineties, the results of several well-conducted clinical trials of most growth factors failed to uphold the optimism with which growth factors had been heralded into the wound-healing scenario. That is, with the exception of PDGF (plateletderived growth factor) that has been shown to have a role in the management of diabetic foot wounds. Positives emerging from all this scientific work include better quality of clinical trials, better quality of publications, and much higher visibility for wound healing. All this benefits science, but those who are charged with managing budgets understandably expect to see financial returns that are based on drugs/devices being used in the clinic. In a world that is being driven by evidence-based medicine, this pathway has become very difficult to negotiate. It is necessary to remind ourselves that chronic wounds include scars, amputations resulting from trauma, and infectious lower extremity wounds, and so on.
How is clinical management to be improved? To an extent we have to ensure that first principles are well adhered to. We also need to return to the drawing board and explore where research should be headed. Do we need miracle cures for chronic wounds or do we need simple, efficacious means of managing complications while adhering to principles of management? We need both. In seeking out a miracle cure, we should also seriously examine and explore to the maximum the role of plant products in wound healing. Such products are indigenous to every society, and the techniques of studying these are applicable universally. We also need training packages that are adopted by the managers of health care in society-such packages are under development under the aegis of the World Union of Wound Healing Societies.
